This decommissioned ERA site remains active temporarily to support our final migration steps to https://ualberta.scholaris.ca, ERA's new home. All new collections and items, including Spring 2025 theses, are at that site. For assistance, please contact erahelp@ualberta.ca.
Search
Skip to Search Results- 1Bekele, Raie Taye
- 1Benesch, Matthew G. K.
- 1Benesch, Matthew GK
- 1Brindley, David N.
- 1Curtis, Jonathan M.
- 1Dewald, Jay
- 4Graduate and Postdoctoral Studies (GPS), Faculty of
- 4Graduate and Postdoctoral Studies (GPS), Faculty of/Theses and Dissertations
- 1Agricultural, Food and Nutritional Science, Department of
- 1Agricultural, Food and Nutritional Science, Department of/Journal Articles (Agricultural, Food and Nutritional Science)
-
Spring 2015
Autotaxin is a secreted enzyme that produces most of the extracellular lysophosphatidate from lysophosphatidylcholine, the most abundant phospholipid in plasma. Lysophosphatidate mediates many physiological and pathological processes by signaling through six G-protein-coupled receptors to promote...
-
Fall 2009
First-line treatment of breast and other cancers with Taxol is compromised by resistance in up to 40% of patients. To improve chemotherapy, it is vital to understand how Taxol resistance develops and to overcome this. Autotaxin (ATX) promotes cancer cell survival, growth, migration, invasion...
-
Lipid phosphate phosphatase-1 expression in cancer cells attenuates tumor growth and metastasis in mice
Download2014
Dewald, Jay, Santos, Webster L., Patwardhan, Neeraj, Zhao, Yuan Y., McMullen, Todd P. W., Curtis, Jonathan M., Brindley, David N., Tang, Xiaoyun, Benesch, Matthew G. K.
Lipid phosphate phosphatase-1 (LPP1) degrades lysophosphatidate (LPA) and attenuates receptor-mediated signaling. LPP1 expression is low in many cancer cells and tumors compared with normal tissues. It was hypothesized from studies with cultured cells that increasing LPP1 activity would decrease...
-
Spring 2010
Increased expression of autotaxin has been shown to promote metastasis formation and cancer proliferation. These actions could be related to the catalytic activity of autotaxin which converts lysophosphatidylcholine into lysophosphatidate extracellularly or non-catalytic functions...
-
Spring 2016
Tamoxifen is the accepted therapy for patients with estrogen receptor α (ERα)−positive breast cancer. However, clinical resistance to tamoxifen, as demonstrated by recurrence or progression on therapy, is frequent and precedes death from metastases. To improve breast cancer treatment it is vital...